BPC-157 Dosage Guide UK: Reconstitution, Research Protocols & Calculator

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide — a 15-amino-acid sequence derived from a naturally occurring protein found in gastric juice. Preclinical research, primarily conducted in rodent models, has examined its effects on tendon healing, ligament repair, muscle recovery, gut health, and neuroprotection.

Key findings from preclinical research: - Tendon and ligament healing: Multiple studies have demonstrated accelerated healing of Achilles tendon, rotator cuff, and medial collateral ligament injuries in rodent models, with histological evidence of improved collagen organisation - Muscle repair: Research suggests BPC-157 may upregulate growth hormone receptor expression in muscle tissue, potentially supporting recovery from damage - Gut health: BPC-157 has shown protective effects against NSAID-induced gut damage and has been studied in the context of inflammatory bowel conditions in animal models - Angiogenesis: The peptide appears to promote blood vessel formation, which may underpin its tissue healing properties

Important caveats: - The vast majority of research is preclinical (animal) — human clinical trial data is extremely limited - BPC-157 is not an approved medication in the UK for any indication - It is classified as a research chemical and its legal status for human use in the UK requires careful consideration - All use outside of approved research settings carries risk and should be approached with appropriate caution

*This guide is intended for educational and research information purposes only. It does not constitute medical advice or encourage the use of research chemicals outside of authorised research contexts.*

Research literature and research community protocols have converged on a dose range of 250–500 micrograms (mcg) per day, administered via subcutaneous or intramuscular injection, as the most commonly cited range for preclinical and early human research contexts.

Dose range breakdown:

• •Low end (250 mcg/day): Often used as a starting point in research protocols; thought to be sufficient for systemic effects and potentially for gut-related research applications
• •Standard range (250–500 mcg/day): The most frequently cited range in research protocols; used for tendon, ligament, and muscle injury research
• •Higher range (500 mcg twice daily): Used in some protocols specifically for significant musculoskeletal injury contexts

Systemic vs localised administration: - Systemic (subcutaneous, away from injury site): Thought to produce body-wide effects through systemic distribution - Localised (near injury site): Some research protocols administer adjacent to the injury area; thought by some researchers to concentrate local effects, though evidence is limited

Frequency: - Most research protocols use once-daily dosing - Some acute injury protocols use twice-daily dosing for the initial phase

Duration: - Typical research cycle length: 4–12 weeks, with 4–6 weeks being common for acute injury protocols and 8–12 weeks for more extended research

*Dose information is derived from preclinical literature and is presented for educational purposes only. These are not clinical recommendations.*

Accurate reconstitution is essential for precise dosing in any research context. The following guide covers the most common reconstitution scenario: a 5mg vial of BPC-157 reconstituted with bacteriostatic water (BAC water).

What you will need: - 5mg vial of lyophilised (freeze-dried) BPC-157 - Bacteriostatic water (0.9% benzyl alcohol in sterile water — preserves the reconstituted peptide) - 1mL or 3mL sterile syringes - Alcohol swabs

Step-by-step reconstitution:

1. Swab the tops of both the peptide vial and BAC water vial with an alcohol swab and allow to dry 2. Draw 2mL of bacteriostatic water into your syringe 3. Inject the BAC water slowly into the peptide vial — direct the stream against the glass side of the vial, not onto the lyophilised powder directly 4. Gently swirl (do not shake) the vial until the powder is fully dissolved 5. The solution should be clear and colourless — do not use if cloudy or particulate matter is visible

Resulting concentration: - 5mg BPC-157 in 2mL BAC water = 2,500 mcg/mL (2.5 mcg per microlitre)

Storage: - Store reconstituted peptide in the refrigerator at 2–8°C - Do not freeze the reconstituted solution - Use within 4–6 weeks of reconstitution (BAC water extends shelf life vs plain sterile water) - Keep away from direct light

*Reconstitution should be performed under sterile conditions. Contamination of research compounds introduces significant experimental error and safety risk.*

Accurate syringe measurement is one of the most important practical aspects of peptide research. The following calculation guide applies to a 5mg BPC-157 vial reconstituted in 2mL BAC water (2,500 mcg/mL).

Insulin syringe unit reference (U-100 syringe): - A U-100 insulin syringe has 100 units per mL - Each unit on the syringe = 0.01mL (10 microlitres)

Dose calculations:

| Target Dose | Volume Required | Syringe Units (U-100) | |---|---|---| | 250 mcg | 0.10 mL | 10 units | | 300 mcg | 0.12 mL | 12 units | | 400 mcg | 0.16 mL | 16 units | | 500 mcg | 0.20 mL | 20 units | | 500 mcg x2 | 0.20 mL x2 | 20 units x2 |

Formula for any dose: Volume (mL) = Target dose (mcg) ÷ Concentration (mcg/mL) Example: 250 mcg ÷ 2,500 mcg/mL = 0.10 mL = 10 units on a U-100 syringe

Tips for accurate measurement: - Always use U-100 insulin syringes (1mL capacity, 28–31 gauge needle) for peptide research — the small graduations allow accurate measurement of small volumes - Draw the solution slowly to avoid air bubbles - Hold the vial inverted when drawing to minimise air introduction - Tap any air bubbles to the top and expel before measuring the final dose

*Syringe units and volume calculations must be double-checked against your specific reconstitution. Different vial sizes or water volumes change the concentration and therefore the syringe units per dose.*

Beyond the dose itself, the timing and cycle structure of BPC-157 administration are important variables in research design.

Morning vs split dosing:

• •Single morning dose: The most common protocol in research literature; provides a daily pulse of the peptide
• •Split dosing (morning and evening): Used in some acute injury research protocols, particularly when the twice-daily higher dose range (500 mcg x2) is employed
• •Pre- and post-activity dosing: Some protocols in physically active research subjects time administration relative to training activity

There is no strong clinical evidence favouring one timing approach over another — the choice is typically driven by practicality and the specific research question.

Recommended cycle lengths:

• •Short cycle (4–6 weeks): Appropriate for acute injury or gastric healing research questions
• •Standard cycle (8–12 weeks): Most commonly used; allows time for the slower processes of collagen remodelling and tissue maturation to be observed
• •Off-cycle period: A common research convention is a rest period equal to the cycle length before re-administration, though there is limited pharmacological data to precisely define optimal cycling

Common research stacks: - BPC-157 + TB-500: The most common combination in tissue repair research; the two peptides are thought to have complementary mechanisms (BPC-157: angiogenesis and cellular repair; TB-500: actin regulation and anti-inflammatory) - BPC-157 + GHK-Cu: Used in some skin and wound healing research contexts

Administration site: - Subcutaneous injection into abdominal fat is the most commonly used route for systemic research protocols - Keep an accurate record of injection sites and rotate to avoid localised irritation

*All information in this guide is for educational and research information purposes only. BPC-157 is not an approved medical treatment in the UK. Consult a qualified researcher and review applicable regulations before use in any context.*